The impact of insurance status on progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)

被引：0
|
作者：
Castro, Daniela [1 ]
Tripathi, Nishita [2 ]
Sayegh, Nicolas [2 ]
Gebrael, Georges [2 ]
Li, Xiaochen [1 ]
Meza, Luis [1 ]
Zengin, Zeynep [1 ]
Chehrazi-Raffle, Alex [1 ]
Govindarajan, Ameish [1 ]
Dizman, Nazli [1 ,3 ]
Ebrahimi, Hedyeh [1 ]
Chawla, Neal [1 ]
Mercier, Benjamin [1 ]
Hsu, Joann [1 ]
Shi, Jessica [1 ]
Philip, Errol [4 ]
Bergerot, Cristiane [5 ]
Barragan-Carrillo, Regina [1 ,6 ]
Pal, Sumanta [1 ]
机构：
[1] City Hope Comprehens Canc Ctr, Dept Med Oncol & Expt Therapeut, Duarte, CA USA
[2] Univ Utah, Huntsman Canc Inst, Div Med Oncol, Salt Lake City, UT USA
[3] Yale Univ, Dept Internal Med, Sch Med, New Haven, CT USA
[4] Univ Calif San Francisco, San Francisco, CA USA
[5] Ctr Canc Brasilia CETTRO, Inst Unity Ensino & Pesquisa, Brasilia, DF, Brazil
[6] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Mexico City, DF, Mexico
来源：
ONCOLOGIST | 2023年 / 28卷
关键词：
insurance status; clinical outcomes; disparities; social determinants of health;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
45
引用
收藏
页码：S5 / +
页数：2
相关论文
共 50 条
  • [21] Early onset hypothyroidism as a predictor for progression-free survival (PFS) and overall survival (OS) benefit in patients with advanced renal cell carcinoma treated with first-line sunitinib
    Pinto, Alvaro
    Garrido, Maria
    Cruz, Patricia
    Lopez, David
    Zambrana, Francisco
    Aguayo, Cristina
    Fellu, Jaime
    Espinosa, Enrique
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [22] Circadian robustness as an independent predictor of prolonged progression-free survival (PFS) and overall survival (OS) in 436 patients with metastatic colorectal cancer (mCRC).
    Levi, Francis
    Parganiha, Arti
    Karaboue, Abdoulaye
    Innominato, Pasquale F.
    Giacchetti, Sylvie
    Garufi, Carlo
    Dispersyn, Garance
    Focan, C. N. J.
    Iacobelli, Stefano
    Bjarnason, Georg A.
    Moreau, Thierry
    Dugue, Pierre Antoine
    Waterhouse, Jim
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [23] Evaluating the relationship between progression-free survival (PFS) and overall survival (OS) in clinical trials of patients (pts) with metastatic colorectal cancer (mCRC)
    Sidhu, R.
    Rong, A.
    Dahlberg, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [24] EFFECT OF REDUCTION OF CIRCULATING TUMOR CELLS (CTCS) ON PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN METASTATIC BREAST CANCER (MBC) PATIENTS
    Giuliano, M.
    Giordano, A.
    Handy, B. C.
    Ueno, N.
    Andreopoulou, E.
    Alvarez, R. H.
    Valero, V.
    Hortobagyi, G. N.
    Reuben, J.
    Cristofanilli, M.
    ANNALS OF ONCOLOGY, 2010, 21 : 32 - 33
  • [25] The relationship between overall survival (OS) and progression-free survival (PFS) in gastrointestinal stromal tumor (GIST).
    Stillman, Ipek Ozer
    Strand, Lauren N.
    Chang, Jane
    Mohamed, Ateesha F.
    Fahrbach, Kyle
    Freier, Katherine E. Tranbarger
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [26] OVERALL SURVIVAL (OS) VERSUS PROGRESSION-FREE SURVIVAL (PFS): IS THERE A RATIONAL FOR REPLACING ONE OUTCOME FOR THE OTHER?
    Teich, V
    Fernandes, R. A.
    VALUE IN HEALTH, 2017, 20 (09) : A863 - A863
  • [27] Examples of Population Kinetics (PopKin) Assessments of Progression-Free (PFS) and Overall Survival (OS)
    Stewart, D.
    Aljassim Alshareef, A.
    Robinson, A.
    Fung-Kee-Fung, M.
    Ong, M.
    Awan, A.
    Ocana, A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1213 - S1213
  • [28] PROGRESSION-FREE AND OVERALL SURVIVAL OF PATIENTS TREATED WITH PRESURGICAL SUNITINIB PRIOR TO CYTOREDUCTIVE NEPHRECTOMY (CN) IN CLEAR CELL SYNCHRONOUS METASTATIC RENAL CELL CARCINOMA (MRCC)
    Bex, Axel
    Blank, Christian
    Chowdhury, Simon
    Nichol, David
    Peters, John
    Horenblas, Simon
    O'Brien, Tim
    Sarwar, Naveed
    Haanen, John
    Powles, Thomas
    JOURNAL OF UROLOGY, 2011, 185 (04): : E709 - E710
  • [29] Association between treatment effects on disease progression (DP) endpoints and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)
    Delea, T. E.
    Khuu, A.
    Kay, A.
    Zheng, J.
    Baladi, J. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [30] Association between biopsychosocial distress (BPSD) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)
    Bergerot, C. D.
    Clark, K. L.
    Ashing, K. T.
    Almeida, L.
    Bergerot, P. G.
    Obenchain, R.
    Dizman, N.
    Hsu, J.
    Maia, M. C.
    Philip, E.
    Loscalzo, M.
    Pal, S. K.
    ANNALS OF ONCOLOGY, 2017, 28
12345